New Trump era could be a boon for bio­phar­ma M&A, deal­mak­ing

As for­mer Pres­i­dent Don­ald Trump re­turns to pow­er — the As­so­ci­at­ed Press pro­ject­ed his pres­i­den­tial vic­to­ry Wednes­day morn­ing — the bio­phar­ma in­dus­try may see the door open …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER